US 9168291
β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
granted A61KA61K2039/585A61K31/7004
Quick answer
US patent 9168291 (β-mannosylceramide and stimulation of NKT cell anti-tumor immunity) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/585, A61K31/7004, A61K31/7032, A61K38/2013